Blueprint Medicines Unveils Promising Long-Term Data for AYVAKIT® in Systemic Mastocytosis at 2025 EHA and EAACI Congresses

Reuters

2025/06/13

Blueprint Medicines Unveils Promising Long-Term Data for AYVAKIT® in Systemic Mastocytosis at 2025 EHA and EAACI Congresses

Blueprint Medicines Corporation has announced the presentation of new data on the long-term clinical efficacy and safety profile of AYVAKIT®/AYVAKYT® (avapritinib) at the 2025 European Hematology Association (EHA2025) Hybrid Congress in Milan, Italy, and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, United Kingdom. These presentations, including one oral and two flash talks, highlight Blueprint Medicines' ongoing efforts to improve treatment for patients with systemic mastocytosis $(SM)$. The data underscore AYVAKIT's role as a durable standard of care for both indolent and advanced SM, and emphasize the real-world burden of the disease. The findings are based on patient data from the PIONEER, PATHFINDER, and EXPLORER trials, with follow-up extending up to five years for indolent SM and 6.5 years for advanced SM. The data presentations are available on the company's website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Blueprint Medicines Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: NE09480) on June 12, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2543561528"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2543561528\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2543561528?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-13 06:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2543561528","market":"us","top_or_hot":-1,"title":"Blueprint Medicines Unveils Promising Long-Term Data for AYVAKIT® in Systemic Mastocytosis at 2025 EHA and EAACI Congresses","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Blueprint Medicines Unveils Promising Long-Term Data for AYVAKIT® in Systemic Mastocytosis at 2025 EHA and EAACI Congresses\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/BPMC\">Blueprint Medicines Corporation</a> has announced the presentation of new data on the long-term clinical efficacy and safety profile of AYVAKIT®/AYVAKYT® (avapritinib) at the 2025 European Hematology Association (EHA2025) Hybrid Congress in Milan, Italy, and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, United Kingdom. These presentations, including one oral and two flash talks, highlight Blueprint Medicines' ongoing efforts to improve treatment for patients with systemic mastocytosis <a href=\"https://laohu8.com/S/SM\">$(SM)$</a>. The data underscore AYVAKIT's role as a durable standard of care for both indolent and advanced SM, and emphasize the real-world burden of the disease. The findings are based on patient data from the PIONEER, PATHFINDER, and EXPLORER trials, with follow-up extending up to five years for indolent SM and 6.5 years for advanced SM. The data presentations are available on the company's website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Blueprint Medicines Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: NE09480) on June 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Blueprint Medicines Unveils Promising Long-Term Data for AYVAKIT® in Systemic Mastocytosis at 2025 EHA and EAACI Congresses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBlueprint Medicines Unveils Promising Long-Term Data for AYVAKIT® in Systemic Mastocytosis at 2025 EHA and EAACI Congresses\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-13 06:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Blueprint Medicines Unveils Promising Long-Term Data for AYVAKIT® in Systemic Mastocytosis at 2025 EHA and EAACI Congresses\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/BPMC\">Blueprint Medicines Corporation</a> has announced the presentation of new data on the long-term clinical efficacy and safety profile of AYVAKIT®/AYVAKYT® (avapritinib) at the 2025 European Hematology Association (EHA2025) Hybrid Congress in Milan, Italy, and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, United Kingdom. These presentations, including one oral and two flash talks, highlight Blueprint Medicines' ongoing efforts to improve treatment for patients with systemic mastocytosis <a href=\"https://laohu8.com/S/SM\">$(SM)$</a>. The data underscore AYVAKIT's role as a durable standard of care for both indolent and advanced SM, and emphasize the real-world burden of the disease. The findings are based on patient data from the PIONEER, PATHFINDER, and EXPLORER trials, with follow-up extending up to five years for indolent SM and 6.5 years for advanced SM. The data presentations are available on the company's website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Blueprint Medicines Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: NE09480) on June 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0053671581.USD","symbol_name":"摩根大通美國小盤成長股 A(dist)","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250612:nNDL90ggv7:1","article_id":"2543561528","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2543561528","pubTimestamp":1749765696,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Blueprint Medicines Corporation has announced the presentation of new data on the long-term clinical efficacy and safety profile of AYVAKIT/AYVAKYT  at the 2025 European Hematology Association  Hybrid Congress in Milan, Italy, and the European Academy of Allergy and Clinical Immunology  Congress 2025 in Glasgow, United Kingdom. These presentations, including one oral and two flash talks, highlight Blueprint Medicines' ongoing efforts to improve treatment for patients with systemic mastocytosis . The data underscore AYVAKIT's role as a durable standard of care for both indolent and advanced SM, and emphasize the real-world burden of the disease. The findings are based on patient data from the PIONEER, PATHFINDER, and EXPLORER trials, with follow-up extending up to five years for indolent SM and 6.5 years for advanced SM. The data presentations are available on the company's website.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","BK4139":"生物科技","BK4505":"高瓴资本持仓","BPMC":"Blueprint Medicines Corporation"},"translate_title":"Blueprint Medicines公布了AYVAKIT有希望的长期数据®2025年EHA和EAACI大会上的系统性肥大细胞增多症","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BPMC":0.9},"content_text":"Blueprint Medicines Unveils Promising Long-Term Data for AYVAKIT® in Systemic Mastocytosis at 2025 EHA and EAACI Congresses\n    \n\nBlueprint Medicines Corporation has announced the presentation of new data on the long-term clinical efficacy and safety profile of AYVAKIT®/AYVAKYT® (avapritinib) at the 2025 European Hematology Association (EHA2025) Hybrid Congress in Milan, Italy, and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, United Kingdom. These presentations, including one oral and two flash talks, highlight Blueprint Medicines' ongoing efforts to improve treatment for patients with systemic mastocytosis $(SM)$. The data underscore AYVAKIT's role as a durable standard of care for both indolent and advanced SM, and emphasize the real-world burden of the disease. The findings are based on patient data from the PIONEER, PATHFINDER, and EXPLORER trials, with follow-up extending up to five years for indolent SM and 6.5 years for advanced SM. The data presentations are available on the company's website.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Blueprint Medicines Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: NE09480) on June 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}